Latest Articles
Women's Health Therapeutics Market Poised for Growth: Innovation, Investment and Global Impact - Lelezard
Women's Health Therapeutics Market Poised for Growth: Innovation, Investment and Global Impact Lelezard
Published: May 8, 2025, 7:24 p.m.
These are the HIV therapeutics startups to watch in 2025 - Labiotech.eu
These are the HIV therapeutics startups to watch in 2025 Labiotech.eu
Published: April 16, 2025, 1:04 p.m.
Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases - Labiotech.eu
Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases Labiotech.eu
Published: April 16, 2025, 6:33 a.m.
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer - The Manila Times
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer The Manila Times
Published: April 7, 2025, 8:16 p.m.
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position - TipRanks
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position TipRanks
Published: April 1, 2025, 6:54 p.m.
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results The Manila Times
Published: March 27, 2025, 10:06 p.m.
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results GlobeNewswire
Published: March 27, 2025, 9:46 p.m.
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results TradingView
Published: March 27, 2025, 9:44 p.m.
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer Business Wire
Published: March 12, 2025, 5:34 p.m.
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... - Yahoo Finance
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ... Yahoo Finance
Published: Feb. 28, 2025, 7:35 a.m.
Link copied to clipboard!